HCPLive Network

Phase 3 Trial of Experimental Gout Drug Lesinurad to Begin

Phase 3 Trial of Experimental Gout Drug Lesinurad to BeginArdea Biosciences announced on Monday that it would soon begin the first of four planned Phase 3 clinical trials of its experimental gout drug lesinurad. The trial is expected to include around 2,000 gout patients at study sites around the world.
Lesinurad is an oral inhibitor of the URAT1 transporter in the kidney that regulates uric acid excretion. According to a press release from Ardea Biosciences, around 90% of gout patients are thought to excrete too little uric acid, and studies have found that defective renal transporters, which promote excretion of uric acid under normal circumstances, are genetically linked to gout.
Since currently available gout drugs such as the xanthine oxidase inhibitors allopurinol and febuxostat have a mechanism of action different from URAT1 inhibitors, the hope is that lesinurad will be able to be used in conjunction with these other drugs to help the many gout patients who are not adequately treated with existing therapies alone. In previous Phase 1 and 2 trials, lesinurad has been tested on over 700 patients as a single agent and in combination with allopurinol and febuxostat.

Further Reading
Gout Living website features a gout attack tracker, information for family, friends and caregivers, and helps patients locate Arthritis Foundation offices.
Two studies highlight the challenges to effective treatment posed by hypertension, diabetes, and other comorbid conditions in patients with gout.
An audit reveals gout patients are not being referred to specialists.
Prior to an FDA ban on unapproved colchicine products, the drugs cost $0.10 a pill. The only FDA-approved colchicine product costs $5 a pill.
Gout Diet - There is no reason for individuals who either have gout or are at risk of developing gout to avoid soyfoods.
Learn about findings from recent studies of gout, crystalline arthritis, and hyperuricemia.
The novel enzyme inhibitor combined with allopurinol demonstrated significantly better serum uric acid control than placebo plus allopurinol.
More Reading